Protective effects of a peroxisome proliferator-activated receptor-β/δ agonist in experimental autoimmune encephalomyelitis

• Published in: Journal of neuroimmunology 2005-11, Vol.168 (1), p.65-75
• Main Authors: Polak, Paul E., Kalinin, Sergey, Dello Russo, Cinzia, Gavrilyuk, Vitaliy, Sharp, Anthony, Peters, Jeffrey M., Richardson, Jill, Willson, Tim M., Weinberg, Guy, Feinstein, Douglas L.
• Format: Article
• Language: English
• Subjects: Animals; Brain - cytology; Brain - drug effects; Brain - immunology; Brain - metabolism; Concanavalin A - pharmacology; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Encephalomyelitis, Autoimmune, Experimental - chemically induced; Encephalomyelitis, Autoimmune, Experimental - prevention & control; Enzyme-Linked Immunosorbent Assay - methods; Female; Gene Expression Regulation, Enzymologic - drug effects; Glycoproteins; Immunohistochemistry - methods; Inflammation; Interferon-gamma - metabolism; Lymphocyte Activation - drug effects; Lymphocytes - drug effects; Lymphocytes - metabolism; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin; Myelin Basic Protein - metabolism; Myelin-Oligodendrocyte Glycoprotein; Neuroglia - drug effects; Neuroglia - metabolism; Oligodendrocyte; Peptide Fragments; PPAR delta - agonists; Reverse Transcriptase Polymerase Chain Reaction - methods; RNA, Messenger - biosynthesis; Severity of Illness Index; Stem cells; Thiazoles - administration & dosage; Time Factors
• ISSN: 0165-5728; 1872-8421
• DOI: 10.1016/j.jneuroim.2005.07.006

Agonists of the peroxisome proliferator-activated receptor gamma (PPARγ) exert anti-inflammatory and anti-proliferative effects which led to testing of these drugs in experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. In contrast, the effect of PPARdelta (PPARδ) agonists in EAE is not yet known. We show that oral administration of the selective PPARδ agonist GW0742 reduced clinical symptoms in C57BL/6 mice that had been immunized with encephalitogenic myelin oligodendrocyte glycoprotein (MOG) peptide. In contrast to previous results with PPARγ agonists, GW0742 only modestly attenuated clinical symptoms when the drug was provided simultaneously with immunization, but a greater reduction was observed if administered during disease progression. Reduced clinical symptoms were accompanied by a reduction in the appearance of new cortical lesions, however cerebellar lesion load was not reduced. Treatment of T-cells with GW0742 either in vivo or in vitro did not reduce IFNγ production; however GW0742 reduced astroglial and microglial inflammatory activation and IL-1β levels in EAE brain. RTPCR analysis showed that GW0742 increased expression of some myelin genes. These data demonstrate that PPARδ agonists, like other PPAR ligands, can exert protective actions in an autoimmune model of demyelinating disease.